A Phase 1 study of the long‐acting anti‐IL‐5 monoclonal antibody GSK3511294 in patients with asthma

Dave Singh; Rainard Fuhr; Nicholas P. Bird; Sarah Mole; Kelly Hardes; Yau Lun Man; Anthony Cahn; Steven W. Yancey; Isabelle J. Pouliquen

doi:10.1111/bcp.15002

A Phase 1 study of the long‐acting anti‐IL‐5 monoclonal antibody GSK3511294 in patients with asthma

Dave Singh
, Rainard Fuhr
, Nicholas P. Bird
, Sarah Mole
, Kelly Hardes
, Yau Lun Man
, Anthony Cahn
, Steven W. Yancey
, Isabelle J. Pouliquen

Division of Immunology, Immunity to Infection and Respiratory Medicine

Research output: Contribution to journal › Article › peer-review

Original language	Undefined
Journal	British Journal of Clinical Pharmacology
DOIs	https://doi.org/10.1111/bcp.15002
Publication status	Published - Feb 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1111/bcp.15002

Cite this

@article{9a8765ab604145cd9d1906faac6fed10,

title = "A Phase 1 study of the long‐acting anti‐IL‐5 monoclonal antibody GSK3511294 in patients with asthma",

author = "Dave Singh and Rainard Fuhr and Bird, \{Nicholas P.\} and Sarah Mole and Kelly Hardes and Man, \{Yau Lun\} and Anthony Cahn and Yancey, \{Steven W.\} and Pouliquen, \{Isabelle J.\}",

year = "2022",

month = feb,

doi = "10.1111/bcp.15002",

language = "Undefined",

journal = "British Journal of Clinical Pharmacology",

issn = "0306-5251",

publisher = "John Wiley \& Sons Ltd",

}

TY - JOUR

T1 - A Phase 1 study of the long‐acting anti‐IL‐5 monoclonal antibody GSK3511294 in patients with asthma

AU - Singh, Dave

AU - Fuhr, Rainard

AU - Bird, Nicholas P.

AU - Mole, Sarah

AU - Hardes, Kelly

AU - Man, Yau Lun

AU - Cahn, Anthony

AU - Yancey, Steven W.

AU - Pouliquen, Isabelle J.

PY - 2022/2

Y1 - 2022/2

UR - https://doi.org/10.1111/bcp.15002

U2 - 10.1111/bcp.15002

DO - 10.1111/bcp.15002

M3 - Article

SN - 0306-5251

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

ER -

A Phase 1 study of the long‐acting anti‐IL‐5 monoclonal antibody GSK3511294 in patients with asthma

UN SDGs

Access to Document

Other files and links

Cite this